



# DURECT to Present at The Wall Street Analyst Forum Institutional Investor Conference

CUPERTINO, Calif., June 9, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at The 25<sup>th</sup> Annual Wall Street Analyst Forum Institutional Investor Conference on Thursday, June 19 at 10:35 a.m. Eastern Time. The conference is being held at the University Club located at 1 West 55<sup>th</sup> Street in New York City.

DURECT Corporation ([www.durect.com](http://www.durect.com)) is pioneering the development and commercialization of pharmaceutical

A live audio webcast of the presentation will be available by accessing <http://www.visualwebcaster.com/event.asp?id=99581>.

A live audio webcast of the presentation will also be available by accessing DURECT's homepage at [www.durect.com](http://www.durect.com) and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy<sup>®</sup>, POSIDUR<sup>®</sup>, ELADUR<sup>®</sup>, and TRANSDUR<sup>®</sup>-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit [www.durect.com](http://www.durect.com).

NOTE: POSIDUR<sup>®</sup>, SABER<sup>®</sup>, ORADUR<sup>®</sup>, TRANSDUR<sup>®</sup>, and DURIN<sup>®</sup> are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR<sup>®</sup> and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

Logo – <http://photos.prnewswire.com/prnh/20020717/DRRXLOGO>

SOURCE DURECT Corporation

Matthew J. Hogan, Chief Financial Officer, DURECT, 408-777-4936